Literature DB >> 10487520

Transforming growth factor-beta responsiveness in DPC4/SMAD4-null cancer cells.

J L Dai1, M Schutte, R K Bansal, R E Wilentz, A Y Sugar, S E Kern.   

Abstract

DPC4/SMAD4 is a candidate tumor suppressor gene with a strikingly high frequency of gene alterations in pancreatic cancer that suggests a discrete role for DPC4 in these tumors. DPC4 tumor-suppressive function has been implicated to mediate the transforming growth factor-beta (TGFbeta)-suppressive pathway; however, in a DPC4-null pancreatic cancer cell line, TGFbeta growth-inhibitory and transcriptional responses were found to be DPC4-independent. This was observed within native cells having a natural homozygous deletion and in clones engineered for stable expression of wild-type DPC4 integrated into the genome. This observation contrasted with the absolute DPC4 dependence of TGFbeta responses in a breast cancer cell line studied in parallel. This growth-inhibitory response to TGFbeta in DPC4-null cells relied on an intact ras effector pathway. These data further suggest a major categorization of TGFbeta responses into DPC4-dependent and -independent signaling pathways and specifically suggest that disruption of the TGFbeta-independent signal might be a basis of selection for the emergence of DPC4 alterations during tumorigenesis in the pancreas and other sites.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10487520     DOI: 10.1002/(sici)1098-2744(199909)26:1<37::aid-mc5>3.0.co;2-6

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  19 in total

Review 1.  TGF-beta signaling in mammary gland development and tumorigenesis.

Authors:  L M Wakefield; E Piek; E P Böttinger
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

2.  Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.

Authors:  Nabeel Bardeesy; Kuang-Hung Cheng; Justin H Berger; Gerald C Chu; Jessica Pahler; Peter Olson; Aram F Hezel; James Horner; Gregory Y Lauwers; Douglas Hanahan; Ronald A DePinho
Journal:  Genes Dev       Date:  2006-11-15       Impact factor: 11.361

3.  Restoration of Smad4 in BxPC3 pancreatic cancer cells attenuates proliferation without altering angiogenesis.

Authors:  Michiya Yasutome; Jason Gunn; Murray Korc
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

Review 4.  TGF-β signaling and its role in the regulation of hematopoietic stem cells.

Authors:  Anuradha Vaidya; Vaijayanti P Kale
Journal:  Syst Synth Biol       Date:  2015-01-29

5.  Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defects.

Authors:  E Montgomery; M Goggins; S Zhou; P Argani; R Wilentz; M Kaushal; S Booker; K Romans; P Bhargava; R Hruban; S Kern
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

6.  Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.

Authors:  R E Wilentz; G H Su; J L Dai; A B Sparks; P Argani; T A Sohn; C J Yeo; S E Kern; R H Hruban
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

7.  Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses.

Authors:  Laurence Levy; Caroline S Hill
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

8.  TGFbeta-mediated signaling and transcriptional regulation in pancreatic development and cancer.

Authors:  V Ellenrieder; M E Fernandez Zapico; R Urrutia
Journal:  Curr Opin Gastroenterol       Date:  2001-09       Impact factor: 3.287

9.  Personalized medicine in pancreatic cancer: prognosis and potential implications for therapy.

Authors:  Christine A Iacobuzio-Donahue
Journal:  J Gastrointest Surg       Date:  2012-06-29       Impact factor: 3.452

10.  Ski promotes tumor growth through abrogation of transforming growth factor-beta signaling in pancreatic cancer.

Authors:  T Ryan Heider; Suzanne Lyman; Robert Schoonhoven; Kevin E Behrns
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.